Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+16.4%		$0.02
$0.00
▼
$0.23
N/AN/A64,867 shs72,827 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
$14.49
-9.4%		$20.48
$11.50
▼
$30.45
N/AN/A1,661 shs687 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-11.71%-24.95%-88.54%
Apollomics, Inc. stock logo
APLMW
Apollomics
+16.35%+17.09%+54.17%+12.12%-29.92%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
0.00%-15.98%-42.26%-47.67%+20.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+16.4%		$0.02
$0.00
▼
$0.23
N/AN/A64,867 shs72,827 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
$14.49
-9.4%		$20.48
$11.50
▼
$30.45
N/AN/A1,661 shs687 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-11.71%-24.95%-88.54%
Apollomics, Inc. stock logo
APLMW
Apollomics
+16.35%+17.09%+54.17%+12.12%-29.92%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
0.00%-15.98%-42.26%-47.67%+20.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
$22.57MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
N/AN/AN/AN/AN/AN/AN/AN/A8/12/2026 (Estimated)

Latest NAMSW, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
8/12/2026N/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
-$0.4726N/AN/AN/A$1.88 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
NewAmsterdam Pharma stock logo
NAMSW
NewAmsterdam Pharma
29N/AN/ANot Optionable

Recent News About These Companies

NewAmsterdam Pharma reports $3.7 million second quarter revenue
August 5 at 7:30 AM  |  quiverquant.comQ
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
July 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925643-newamsterdam-pharma-obicetrapib-is-more-than-another-ldl-lowering-pill?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
NewAmsterdam Pharma: Advancing EU Launch and CV Outcomes Pathway Underpins Unchanged $48 Price Target and Buy Rating
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/newamsterdam-pharma-advancing-eu-launch-and-cv-outcomes-pathway-underpins-unchanged-48-price-target-and-buy-rating-ratings-news?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-pharma-wins-ema-backing-for-obicetrapib-therapies?utm_source=marketbeat.com&utm_medium=referral
Top Executive Makes Major Move With NewAmsterdam Pharma Shares
July 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-executive-makes-major-move-with-newamsterdam-pharma-shares-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma Announces COO Transition and Advisory Role
July 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-pharma-announces-coo-transition-and-advisory-role?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-shareholders-approve-espp-and-governance-proposals?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
April 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-pharma-announces-chief-accounting-officer-transition-agreement?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891222-newamsterdam-pharma-cholesterol-lowering-player-risk-on-buy-today?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
April 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/newamsterdam-pharma-undervalued-growth-story-with-upcoming-clinical-catalysts-supporting-buy-rating-ratings-news?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma Director Makes Major Stock Move in High-Value Sale
March 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/newamsterdam-pharma-director-makes-major-stock-move-in-high-value-sale-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Massive Insider Move at NewAmsterdam Pharma Shakes Up Investor Buzz
March 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/massive-insider-move-at-newamsterdam-pharma-shakes-up-investor-buzz-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
March 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-highlights-obicetrapib-progress-in-investor-presentation?utm_source=marketbeat.com&utm_medium=referral
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
February 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/reaffirming-buy-on-newamsterdam-pharma-optimized-expense-outlook-and-milestone-upside-strengthen-risk‑reward-profile-ratings-news?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
February 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/newamsterdam-pharma-nams-buy-rating-on-strong-prevail-momentum-broad-phase-3-cardiovascular-program-and-solid-cash-runway-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Top Executive Makes Major Move With NewAmsterdam Pharma Shares
January 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-executive-makes-major-move-with-newamsterdam-pharma-shares-insider-trading?utm_source=marketbeat.com&utm_medium=referral
Top Executive Makes Bold Move With Major NewAmsterdam Pharma Stock Sale
January 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-executive-makes-bold-move-with-major-newamsterdam-pharma-stock-sale-insider-trading?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/newamsterdam-pharma-prevail-parallels-robust-trial-execution-and-2026-milestones-support-buy-rating-ratings?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
January 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/newamsterdam-pharma-obicetrapib-momentum-2026-inflection-catalysts-and-undervalued-blockbuster-potential-support-buy-rating-ratings?utm_source=marketbeat.com&utm_medium=referral
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
January 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newamsterdam-pharma-outlines-2026-goals-after-strong-2025-progress?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 08/5/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+16.35%)
As of 08/6/2026 03:59 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 08/5/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMSW

$14.49 -1.51 (-9.44%)
As of 08/5/2026 02:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas